Journal Article

FZJ-2019-01932

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png The Combination of DAT-SPECT, Structural and Diffusion MRI Predicts Clinical Progression in Parkinson’s Disease

Lorio, S. (Corresponding author) ; Sambataro, F. ; Bertolino, A. ; Draganski, B. ; Dukart, J.FZJ*

2019
Frontiers Research Foundation Lausanne

This record in other databases:      

Please use a persistent id in citations: http://hdl.handle.net/2128/21853  doi:10.3389/fnagi.2019.00057

Abstract: There is an increasing interest in identifying non-invasive biomarkers of disease severityand prognosis in idiopathic Parkinson’s disease (PD). Dopamine-transporter SPECT(DAT-SPECT), diffusion tensor imaging (DTI), and structural magnetic resonance imaging(sMRI) provide unique information about the brain’s neurotransmitter and microstructuralproperties. In this study, we evaluate the relative and combined capability of theseimaging modalities to predict symptom severity and clinical progression inde novoPDpatients. To this end, we used MRI, SPECT, and clinical data ofde novodrug-naïvePD patients (n= 205, mean age 61±10) and age-, sex-matched healthy controls(n= 105, mean age 58±12) acquired at baseline. Moreover, we employed clinical dataacquired at 1 year follow-up for PD patients with or withoutL-Dopa treatment in orderto predict the progression symptoms severity. Voxel-based group comparisons andcovariance analyses were applied to characterize baseline disease-related alterations forDAT-SPECT, DTI, and sMRI. Cortical and subcortical alterations inde novoPD patientswere found in all evaluated imaging modalities, in line with previously reported midbrain-striato-cortical network alterations. The combination of these imaging alterations wasreliably linked to clinical severity and disease progression at 1 year follow-up in thispatient population, providing evidence for the potential use of these modalities asimaging biomarkers for disease severity and prognosis that can be integrated intoclinical trials.

Note: FUNDINGData used in the preparation of this article were obtainedfrom the PPMI database (www.ppmi-info.org/data). For up-to-date information on the study, visit www.ppmi-info.org.PPMI – a public-private partnership – is funded by theMichael J. Fox Foundation for Parkinson’s Research andfunding partners, including Abbvie, Avid Radiopharmaceuticals,Biogen Idec, Briston-Myers Squibb, Covance, GE Healthcare,Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, MesoScale Discovery, Pfizer, Piramal, Roche, and UCB. SL wassupported by the National Institute for Health ResearchBiomedical Research Centre at Great Ormond Street Hospitalfor Children NHS Foundation Trust, The Henry Smith Charity,and Action Medical Research (GN2214). BD was supportedby the Swiss National Science Foundation (project grant no.32003B_159780 and SPUM 33CM30_140332/1), FoundationParkinson Switzerland, Foundation Synapsis. LREN is gratefulto the Roger de Spoelberch and the Partridge Foundations fortheir generous support

---

Contributing Institute(s):

1. Gehirn & Verhalten (INM-7)

Research Program(s):

1. 572 - (Dys-)function and Plasticity (POF3-572) (POF3-572)

Appears in the scientific report 2019

---

Database coverage:
; ; ; ; BIOSIS Previews ; Clarivate Analytics Master Journal List ; DOAJ Seal ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---